Edition:
United Kingdom

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

6.95USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$6.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,065
52-wk High
$13.50
52-wk Low
$6.12

Latest Key Developments (Source: Significant Developments)

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

Cellect Biotechnology reports Q2 loss per share $0.01
Thursday, 1 Sep 2016 

Cellect Biotechnology Ltd : Cellect Biotechnology Ltd provides corporate update and reports second quarter 2016 financial results .Q2 loss per share $0.01.  Full Article

Cellect Biotechnology sees U.S. IPO of 1.3 mln American depositary shares
Tuesday, 26 Jul 2016 

Cellect Biomed Ltd :Cellect Biotechnology Ltd sees U.S. IPO of 1.3 million American depositary shares - SEC filing.  Full Article

Cellect Biomed files for U.S. IPO of up to $10 mln - SEC Filing
Thursday, 7 Jul 2016 

Cellect Biomed Ltd: Files for U.S. IPO of up to $10.0 million - SEC Filing . Intends to apply to list ADSS on Nasdaq capital market . Proposed IPO price is an estimate solely for purpose of calculating sec registration fee .Rodman Renshaw and Chardan Capital Markets are the underwriters to IPO.  Full Article

BRIEF-Cellect Biotechnology Successfully Completed Proof Of Concept Testing For First Scalable Production Of Apotainer

* SUCCESSFULLY COMPLETED PROOF OF CONCEPT TESTING FOR FIRST SCALABLE PRODUCTION OF APOTAINER Source text for Eikon: Further company coverage:

No consensus analysis data available.